Compare Summit Therapeutics Inc (SMMT) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. Which is the better fit depends on your goals.
| SMMT | VCIT | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Fixed Income |
52-Week High | $29.32 | $84.82 |
52-Week Low | $13.05 | $81.45 |
Enterprise Value | $9.90B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
